Journal
BRAIN
Volume 140, Issue -, Pages 1128-1146Publisher
OXFORD UNIV PRESS
DOI: 10.1093/brain/awx005
Keywords
neurodegeneration; tauopathy; autophagy; proteasome
Categories
Funding
- Tau consortium [P50 AG02350, P01 AG019724, R01AG038791, U54NS092089, F31 NS084556]
- Alzheimer's Research UK
- Wellcome Trust [095317/Z/11/Z, 100140/Z/12/Z]
- NIHR Biomedical Research Unit in Dementia at Addenbrooke's Hospital
- John Douglas French Alzheimer's Foundation
- DFG fellowship
- BBSRC project [BB/L000830/1]
- National Institute on Aging (NIA) [U24 AG21886]
- BBSRC [BB/L000830/1] Funding Source: UKRI
- Alzheimers Research UK [ARUK-TC2015-1, ARUK-TC2015-2] Funding Source: researchfish
Ask authors/readers for more resources
Mutations in the gene encoding tau ( MAPT) cause frontotemporal dementia spectrum disorders. A rare tau variant p.A152T was reported as a risk factor for frontotemporal dementia spectrum and Alzheimer's disease in an initial case-control study. Such findings need replication in an independent cohort. We analysed an independent multinational cohort comprising 3100 patients with neurodegenerative disease and 4351 healthy control subjects and found p. A152T associated with significantly higher risk for clinically defined frontotemporal dementia and progressive supranuclear palsy syndrome. To assess the functional and biochemical consequences of this variant, we generated transgenic zebrafish models expressing wild-type or A152T-tau, where A152T caused neurodegeneration and proteasome compromise. Impaired proteasome activity may also enhance accumulation of other proteins associated with this variant. We increased A152T clearance kinetics by both pharmacological and genetic upregulation of autophagy and ameliorated the disease pathology observed in A152T-tau fish. Thus, autophagy-upregulating therapies may be a strategy for the treatment for tauopathies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available